Two weeks ago received NIH grant to prepare IND for novel Alzheimer's drug. 46 million shares outstanding, 50% institutional ownership. Up today on over five times average volume.
I'm assuming that this drop had something to do with the statement in the presentation that even if sumatriptan is approved in 2015, it won't be launched until sometime next year because at one point they had pretty much given up on it.
If Republicans are genuinely interested in controlling Medicare costs, there could actually be a chance for a bipartisan discussion of the subject of high cost drugs.
The only reason there hasn't been more dilution is that hapless Meda forked over $80 million for the US rights to Onsolis.
Cost effectiveness may be an increasingly important argument for CHEMOSAT. Did you notice that the UK recently dropped coverage for Avastin and some other high-priced drugs? Cost is increasingly an issue in the US as well.
It's normally six months from the resubmission date to the decision date. Generally confirmed by the FDA two months after the resubmission. Any back and forth will mainly be handled by Braeburn.
Why would ATRS lose credibility if Epi AB is not approved? All they have done is pass along how Teva.feels about it.
Without Epi AB I would be waiting for $1.25 or less, preferably a dip below $1. And I would want any buy to be a lot closer to the QST NDA.
Dialogue with FDA "encouraging," optimistic about peak sales, refers to drug as a "growth asset." The good thing about Endo is that they don't have to invent a sales force
First the uneven playing field caused by being outside the standard REM, then the appearance issues. Finally it may get a decent shot at at least modest success.
It was an Australian company. The drugs were "formerly" marketed in the US. The Aussies get an undisclosed cut.
So with carl's discovery it would take two three month implants to do what Probuphine does with one six month one How does that make Probuphine obsolete?